ARS Pharmaceuticals Company Insiders
| SPRY Stock | 10.21 0.36 3.41% |
ARS Pharmaceuticals employs about 162 people. The company is managed by 12 executives with a total tenure of roughly 378 years, averaging almost 31.0 years of service per executive, having 13.5 employees per reported executive. Break down of ARS Pharmaceuticals' management performance can provide insight into the company performance.
ARS Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.1922) % which means that it has lost $0.1922 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4592) %, meaning that it created substantial loss on money invested by shareholders. ARS Pharmaceuticals' management efficiency ratios could be used to measure how well ARS Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.ARS Pharmaceuticals holds a total of 98.85 Million outstanding shares. The majority of ARS Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ARS Pharmaceuticals to benefit from reduced commissions. Therefore, institutional investors are subject to a different set of regulations than regular investors in ARS Pharmaceuticals. Please pay attention to any change in the institutional holdings of ARS Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that nearly three million eight hundred eighty-four thousand seven hundred fifty invesors are currently shorting ARS Pharmaceuticals expressing very little confidence in its future performance.
Some institutional investors establish a significant position in stocks such as ARS Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of ARS Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
ARS Pharmaceuticals Workforce Comparison
ARS Pharmaceuticals is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 976. ARS Pharmaceuticals retains roughly 162 in number of employees claiming about 17% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.56) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.64) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.64. ARS Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ARS Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on ARS Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ARS Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ARS Pharmaceuticals Notable Stakeholders
An ARS Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ARS Pharmaceuticals often face trade-offs trying to please all of them. ARS Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ARS Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MD MBA | CoFounder Officer | Profile | |
| Kathleen CPA | Chief Officer | Profile | |
| Alexander Esq | Chief Secretary | Profile | |
| Daniel Relovsky | Senior Marketing | Profile | |
| Eric Karas | Chief Officer | Profile | |
| Lynda Harris | Vice Resources | Profile | |
| Justin Chakma | Chief Secretary | Profile | |
| Brian MS | SVP Management | Profile | |
| MBA MBA | Ex Strategy | Profile | |
| Robert Bell | CoFounder Officer | Profile | |
| Harris MBA | Executive Strategy | Profile | |
| MBA MS | President, Founder | Profile |
About ARS Pharmaceuticals Management Performance
The success or failure of an entity such as ARS Pharmaceuticals often depends on how effective the management is. ARS Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ARS management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ARS management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the imprecision that can be found in ARS Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ARS Pharmaceuticals. Check ARS Pharmaceuticals' Beneish M Score to see the likelihood of ARS Pharmaceuticals' management manipulating its earnings.
ARS Pharmaceuticals Workforce Analysis
Traditionally, organizations such as ARS Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ARS Pharmaceuticals within its industry.ARS Pharmaceuticals Manpower Efficiency
Return on ARS Pharmaceuticals Manpower
| Revenue Per Employee | 550.3K | |
| Revenue Per Executive | 7.4M | |
| Net Income Per Employee | 49.4K | |
| Net Income Per Executive | 666.5K | |
| Working Capital Per Employee | 1.9M | |
| Working Capital Per Executive | 25.9M |
Additional Tools for ARS Stock Analysis
When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.